Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

By S. Yusuf, M. Pfeffer, K. Swedberg, C. Granger, P. Held, J. McMurray, E. Michelson, B. Olofsson, J. Ostergren. The Lancet, 2003

2,975 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. (2014, background): “Approximately 40% to 50% of HHF patients are female, a group of patients that have traditionally been underrepresented in clinical trials (29), with 1 notable exception (30).”
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2012, methodology): “† The 3023-patient Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Preserved trial, which showed no reduction in the primary composite endpoint (cardiovascular death or HF hospitalization).(139) † The 850-patient Perindopril for Elderly People with Chronic He”
Epidemiology and clinical course of heart failure with preserved ejection fraction (2011, background): “These studies have reported that lower BMI, lower SBP, and lower total cholesterol are all markers of increased mortality risk in HFPEF, thereby extending the reverse epidemiology concept beyond HFREF.64,65 The impact of aetiology of HFPEF on mortality risk is less clear, with conflicting reports in”